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Abstract Metnase is a fusion gene comprising a SET
histone methyl transferase domain and a transposase
domain derived from the Mariner transposase. This fusion
gene appeared ﬁrst in anthropoid primates. Because of its
biochemical activities, both histone (protein) methylase
and endonuclease, we termed the protein Metnase (also
called SETMAR). Metnase methylates histone H3 lysine
36 (H3K36), improves the integration of foreign DNA, and
enhances DNA double-strand break (DSB) repair by the
non-homologous end joining (NHEJ) pathway, potentially
dependent on its interaction with DNA Ligase IV. Metnase
interacts with PCNA and enhances replication fork restart
after stalling. Metnase also interacts with and stimulates
TopoIIa-dependent chromosome decatenation and regu-
lates cellular sensitivity to topoisomerase inhibitors used as
cancer chemotherapeutics. Metnase has DNA nicking and
endonuclease activity that linearizes but does not degrade
supercoiled plasmids. Metnase has many but not all of the
properties of a transposase, including Terminal Inverted
Repeat (TIR) sequence-speciﬁc DNA binding, DNA
looping, paired end complex formation, and cleavage of
the 50 end of a TIR, but it cannot efﬁciently complete
transposition reactions. Interestingly, Metnase suppresses
chromosomal translocations. It has been hypothesized
that transposase activity would be deleterious in primates
because unregulated DNA movement would predispose
to malignancy. Metnase may have been selected for in
primates because of its DNA repair and translocation
suppression activities. Thus, its transposase activities
may have been subverted to prevent deleterious DNA
movement.
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Introduction
Transposons are ancient mobile DNA elements that encode
the enzymatic machinery for their mobility, and are found
in genomes of species from bacteria to mammals (Miskey
et al. 2005). These mobile elements move within genomes
by two major mechanisms: (1) an excision and ligation
strategy utilized by DNA transposons, and (2) by forming
RNA intermediates in the case of retrotransposons. DNA
transposon sequences may comprise up to 3% of the human
genome, whereas retrotransposon sequences may comprise
*41% of the human genome (Lander et al. 2001). The
ratio of these two large classes differs signiﬁcantly among
species. The Tc1/Mariner family is one of the most widely
studied DNA transposons. Its members are present as
defective remnants in vertebrate species. There are three
active Mariner transposon elements observed in insects,
while there are two types of Mariner remnants in primates,
designated Hsmar1 and Hsmar2. Mariner transposons
entered primate genomes approximately 50 million years
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DOI 10.1007/s10709-010-9452-1ago, and remained mobile until 37 million years ago. They
are between 1,300 and 2,400 bp in length and comprise a
central region encoding the transposase activity, and
two ﬂanking Terminal Inverted Repeats (TIR) that mediate
the binding of transposase protein to the transposon
sequences, which results in the excision and ligation-
mediated genome mobility of active transposons (Plasterk
et al. 1999).
The Tc1/Mariner family usually integrates into TA
target dinucleotides in TIR sequences in the host genome
(Plasterk et al. 1999). Phylogenetic relationships among
these transposons are inconsistent with those of their hosts,
so that very similar Tc1/Mariner transposons can be found
in very different organisms such as insects and primates.
This latter observation has been explained by the horizontal
spread of these transposable elements between species,
which took place millions of years ago in vertebrates.
The modes of transmission between species are unknown,
but potential vectors would be viruses and intracellular
parasites (Miskey et al. 2005), although DNA transposons
are not directly infectious. Following initial transmission,
the transposons would have to colonize germ lines
to persist across generations within a species. During this
initial period, massive ampliﬁcation of these elements
takes place. Subsequent mutations accumulate, result-
ing in defective copies in a process called vertical
inactivation.
There is no known transposase activity documented in
primates, with the possible exception of the transposition-
like reaction mediated by the two RAG recombinases
during immunoglobulin and T-cell receptor formation. The
human genome project has identiﬁed 47–50 genes that
could have originated from transposons, 43 of them from
DNA transposons (Lander et al. 2001). It was hypothesized
that these transposon genes have been inactivated, with the
exception of the RAG proteins, because unregulated DNA
mobility would be deleterious to primates, producing either
apoptosis or malignancy (Beck et al. 2008; Lander et al.
2001).
The transposase family of enzymes contains a catalytic
domain termed the DDE or DDD motif, that includes three
conserved amino acids shared by transposases, RAG pro-
teins, HIV integrase, RNAse H, and the RNA-induced
silencing complex (RISC) (Dreyfus 2006). Since transpo-
sons mediate chromosomal translocations in certain
organisms such as maize (Zhang et al. 2009), we theorized
that a transposase activity might play a role in chromosomal
translocations seen in neoplasia in primates. We focused on
an EST clone (ﬁrst noted by Robertson and Zumpano 1997)
that encoded a putative open reading frame that was des-
ignated SETMAR by the National Center for Biotechnology
Information (NCBI). Most transposase sequences in the
human genome are pseudogenes, and not translated; so we
isolated and characterized the protein encoded by this
sequence, to prove that it was indeed translated into a
functional protein. We then characterized its biochemical
activities, and termed it Metnase (Lee et al. 2005). This
gene represents a fusion between a SET histone methylase
domain and a transposase sequence element from Hsmar1
of the human Mariner transposons. The various functions of
Metnase are documented in Table 1.
Metnase structure and evolutionary history
Metnase has three exons that extend over 13.8 Kb located
at 3p26 (Lee et al. 2005). There are multiple types of
human malignancies with cytogenetic abnormalities in this
region, notably non-Hodgkin’s lymphoma, acute leuke-
mias, hereditary prostate cancer, myeloma, and myelo-
dysplastic syndromes. Assessing Metnase gene sequence
and function in these malignancies is an important area of
future study. Two exons form the SET, pre-SET and post-
SET domains (Fig. 1). The third exon is the Mariner
transposase sequence, which is not ﬂanked by a TIR
sequence. The amino acid sequence of the transposase is
most similar to Planarian Mariner-9, with which it has
50% identity. The SET domain is most related to SuvHar91
histone methyl transferase, with 36% homology. The
crystal structure of Metnase has been deposited in the
structure database (histone methylase domain 3B05,
transposase domain 3F2k) although not published, and it
appears that Metnase exists as a dimer. We have conﬁrmed
this dimerization biochemically (unpublished).
One report detailed the evolution of this fusion gene
(Cordaux et al. 2006). Metnase exists only in anthropoid
primates(Humans,apes,andoldandnewworldmonkeys).It
is not found in prosimians or lower mammals. It appears to
have emerged 40–58 million years ago. Detailed genetic
analysis clariﬁed the mechanism of exon capture of the
coding region of Hsmar1 transposase and the creation of a
fusion gene with thetwo SET exons (Cordauxetal. 2006).It
is interesting to note that this same period witnessed the
signiﬁcant transposon invasion and expansion in primates
(Lander et al. 2001; Miskey et al. 2005). By comparing the
rate of non-synonymous (KA) and synonymous (KS) nucle-
otide substitutions per site in the transposase region of each
anthropoidlineage,itwasshownthattheKA/KSratiosamong
different primate lineages were not signiﬁcantly different.
This suggested that the Mariner region has evolved consis-
tently under purifying selection in all anthropoid lineages.
ByevaluatingdifferentregionswithinthetransposaseDNA,
it was found that the 50 half of the exon 3 transposase
sequence (the TIR binding region) displayed a strong signal
of purifying selection (KA/KS = 0.1, signiﬁcantly \1),
whereasthe30 half(thecatalyticregion)displayedasignalof
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Mariner portion of Metnase may have been recruited for a
function located in the N-terminal DNA binding region of
the transposase (Cordaux et al. 2006). However, as we
describebelow,Metnaseretainssomecatalyticactivityofits
transposase domain, at least in vitro in various experimental
settings.
Histone methylase activity of Metnase
Metnase stimulates the dimethylation of histone H3 at
lysine 36 (H3K36me2), and to a lesser extent H3 on lysine
4 (H3K4me2) (Lee et al. 2005). Histone methylation has
emerged as a major regulator of chromatin functions, such
as transcription, DNA repair, DNA replication, imprinting,
and X-chromosome inactivation (Kouzarides 2007). H3K4
and H3K36 methylation have been associated with chro-
matin that is accessible to transcription regulators and
DNA repair proteins (Bernstein et al. 2005). The current
evidence indicates that histone methylation creates docking
sites for other proteins, recruiting them for transcription or
repair. For example, H3K36 methylation attracts the his-
tone deacetylase Rpd3S, which compacts chromatin in the
middle of transcribed genes, and inhibits spurious initiation
of transcription during the elongation phase (Carrozza et al.
2005). While H3K4 methylation has been noted largely in
the promoter areas of genes, H3K36 methylation peaks in
Table 1 Documented Metnase functions
Function/property Assay(s) Comments Reference
Promotes NHEJ Plasmid transfection/rescue Requires SET and nuclease domains Lee et al. (2005)
Histone H3K36 methylase In vitro May promote recruitment of NHEJ components Lee et al. (2005)
Promotes DNA integration Plasmid and viral DNA
transfection
No sequence speciﬁcity for integrating DNA;
target speciﬁcity unknown
Lee et al. (2005)
Enhances IR resistance Colony formation Probably NHEJ dependent Lee et al. (2005)
LigIV interaction Co-IP Probably underlies NHEJ role Hromas et al. (2008)
Suppresses large NHEJ
deletions
Plasmid transfection/rescue May promote limited 50 overhang end-processing Hromas et al. (2008)
Promotes lentivirus
integration
Lentivirus infection Protects viral DNA ends; enhances speciﬁc
targeting (regional, not sequence speciﬁc)
Williamson et al. (2008a)
Interacts with hPso4 Co-IP Interaction required for Metnase recruitment to
DSBs
Beck et al. (2008)
Interacts with NBS1 Co-IP/colocalization in IR-
induced foci
Depends on hPso4 interaction Beck et al. (2008)
Interacts with TopoIIa co-IP, co-localization Co-localization maximum in M phase
(decatenation)
Williamson et al. (2008b)
Promotes TopoIIa-
dependent decatenation
kDNA decatentation;
decatenation checkpoint
Role in M phase; possible role in S phase;
blocked by SAM
Williamson et al. (2008b),
Wray et al. (2009a, b)
Cleaves supercoiled and 50
fork DNAs
In vitro cleavage Requires transposase domain DDN motif Roman et al. (2007)
Binds/nicks Hsmar1 repeats Gel mobility shift, in vitro
cleavage
Weak Hsmar1 cleavage Miskey et al. (2007)
Binds/nicks Hsmar1 In vitro cleavage and
transposition
No transposition activity; may promote DNA
integration into Mariner remnants
Liu et al. (2007)
Binds Hsmar1 TIR In vitro gel shift Independent of hPso4 Beck et al. (2008)
Binds non-TIR DNA In vitro gel shift Requires hPso4 Beck et al. (2008)
Enhances resistance to
topoisomerase inhibitors
Cell survival May regulate tumor resistance to certain
chemotherapeutics
Wray et al. (2009a, b)
Automethylated Mass spectrometry Regulates TopoIIa decatenation activity in vitro Williamson et al. (2008b)
Enhances stalled replication
fork restart
DNA ﬁber analysis Normal fork progression not altered DeHaro et al. (2010)
Fig. 1 Metnase gene structure: Exons 1 and 2 encode the pre-SET,
SET and the post-SET domains. Exon 3 encodes the transposase
domain, which includes an HTF motif that mediates TIR binding. The
catalytic activity of transposases lies in the DDD/E-like motif, which
in Metnase is DDN, which may account for the lack of certain
transposase activities. Metnase is phosphorylated at S495 by Chk1
after DNA damage (unpublished data)
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123the middle and towards the 3‘ end of transcribed genes
(Bernstein et al. 2007). While the consequences of H3K36
methylation are clear as far as suppression of spurious
transcription initiation, its impact on activation of gene
transcription is not as clear. The methyltransferase Setd2
(also termed Set2) mediates trimethylation of H3K36, and
it binds the phosphorylated tail of RNA polymerase II,
which implicates H3K36 in transcription (Li et al. 2002).
Setd2 mediates H3k36 trimethylation in mammalian cells,
but not di- or mono-methylation (Edmunds et al. 2008).
These data raise the possibility that Metnase or other
H3K36 dimethyltransferases (G9a, Smyd2) may be needed
to create dimethylated H3K36 before Setd2 acts. In Dro-
sophila, dimethylation of H3K36 peaks adjacent to pro-
moters and requires distinct methyltransferases than those
that mediate trimethylation of H3K36, which accumulates
toward the 30 end of genes (Bell et al. 2007).
Metnase may play a role in other histone modiﬁcations
besides H3K36me2. Metnase was shown to interact with
Pso4 (also termed Prp19) in a co-immunoprecipitation
assay (Beck et al. 2008). The interaction of Metnase with
Pso4 is essential for the localization of Metnase to sites of
DNA DSBs, and is therefore important for Metnase DNA
repair activity. However, Pso4 is a component of a com-
plex instrumental in RNA splicing, which takes place in the
vicinity of the transcriptional machinery on nascent RNA.
This association of Metnase with Pso4 suggests a potential
role in RNA transcription and splicing through methylation
of H3K36 or other protein targets. As discussed below, the
Metnase transposase domain has potent DNA looping
activity in vitro (Liu et al. 2007). It would be interesting to
determine if this activity was involved in RNA looping
during splicing. The evolution of prosimians to anthropoid
primates may have been associated with a selective pres-
sure for more accurate and efﬁcient transcription and
splicing, in order to provide novel protein functions with a
similar number of gene sequences (Kriventseva et al.
2003). The activity of Metnase on H3K4 is less prominent
than H3K36, at least in vitro. It is unknown if other factors
enhance this activity in vivo (Fig. 2).
Residual transposase functions of Metnase
Metnase binds to a speciﬁc 19 bp sequence within the
consensus Hsmar1 TIR (Kouzarides 2007). Similar to other
Mariner transposases, the Metnase Helix-Turn-Helix
(HTH) motif accounts for this binding; speciﬁcally the
R432 residue within the HTH region is essential for this
binding (Roman et al. 2007). In human genomes there are a
large number of miniature inverted-repeat transposable
elements (MITES). If the solo TIRs are added to the
number of MITES, there are approximately 7,000 potential
Metnase binding sites within the human genome. But as
described above (Fig. 1), Metnase binds to Pso4, which can
bind indiscriminately to double-stranded DNA. Thus, its
interaction with Pso4 could theoretically provide non-spe-
ciﬁc access of Metnase to DNA (Beck et al. 2008). We
mentioned earlier that synonymous versus non-synony-
mous mutation analysis of the Metnase transposase
sequence suggested a selective pressure towards preserving
the DNA binding region rather than the catalytic domain,
consistent with its ability to enhance DNA repair. How-
ever, Metnase still retains many characteristics of ancestral
Mariner transposases. These include TIR DNA binding,
cleavage of 50 end of the transposon in the presence of
Mn
2?, DNA looping, assembly of a paired end complex,
and integration at TA sites (Liu et al. 2007; Miskey et al.
2007). Metnase is efﬁcient in 50 nicking of Hsmar1 trans-
posons in vitro. However, Metnase displayed a severe
defect in cleavage of 30 ends, which limits its ability to
mobilize transposons in vivo, and makes it unlikely that
Metnase could transpose DNA elements in primates (Liu
et al. 2007). This defective 30 nicking phenotype was also
simultaneously demonstrated by another group, who sug-
gested that Metnase generates 50 nicks rather than complete
DSBs, which they found could be induced by reconstructed
functional Hsmar1 transposase (Miskey et al. 2007)( F i g .3).
The Metnase transposase catalytic domain does not
preserve the conserved DDD (Asp in the carboxy terminal
position) or DDE (Glu) triplet motifs of active transpos-
ases; rather it has a DDN (Asn) conﬁguration. Isolated
exon 3 protein of Metnase, encoding the transposase
domain, resulted in extremely weak in vitro transposition
of a reconstructed Hsmar1 transposon (Liu et al. 2007).
Restoration of the DDD motif in the exon 3 protein slightly
increased the frequency of transposition (Liu et al. 2007).
While Metnase does not have full endonuclease activity for
linear DNA, we found that it does indeed have endonu-
clease activity for DNA with tertiary structure, including
supercoiled DNA. Metnase converts supercoiled plasmid
DNA to relaxed circles, and to a lesser extent to linear
forms, but it does not further degrade linear DNA (Roman
Fig. 2 Potential Metnase binding sites in the human genome. There
are about 200 copies of the defective Mariner ancestor Hsmar1, about
2,500 copies of MITES, which are similar to Tc1/Mariner transposons
but lack central elements. There are also about 4,500 solo TIR
sequences
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Metnase is essential for these endonuclease and nicking
activities, but TIR sequences are not required and Metnase
appears to cleave supercoiled DNA without any sequence
speciﬁcity (Miskey et al. 2007; Roman et al. 2007). Thus,
with linear DNA, Metnase has 50 endonuclease activity that
is speciﬁc for TIR sequences, but with supercoiled DNA it
has non-speciﬁc nicking (endonucleolytic) activity.
Metnase in foreign DNA integration
Since Metnase encodes a transposase domain (albeit a
defective one) that has similarity to the catalytic domains
of retroviral integrases, we postulated that Metnase might
enhance viral DNA integration into host genomic DNA.
We found that Metnase enhances Molony Leukemia virus
DNA integration by fourfold (Lee et al. 2005). It also
promotes plasmid DNA integration by 2.6 to 6 fold, whe-
ther the integrating plasmid expresses Metnase (cis inte-
gration) or on a separate plasmid (trans integration) (Lee
et al. 2005). Metnase is also capable of further enhancing
foreign DNA integration into DSBs induced by I-SceI
nuclease (unpublished results). Conversely, reducing
Metnase levels by siRNA decreased plasmid and viral
DNA integration (Lee et al. 2005). This led us to examine
whether Metnase levels inﬂuenced genomic integration of
intact HIV infecting human cells. We found that Metnase
over-expression was accompanied by an increase in the
number of copies of integrated HIV cDNA, whereas
reducing the Metnase level decreased the amount of HIV
cDNA copies integrated in the target human cell genomes
(Williamson et al. 2008a). Metnase had no effect on the
amount of either total cellular viral RNA, cDNA, or dou-
ble-LTR circles after infection, indicating that Metnase
increases cDNA integration into the host genome, without
affecting other infection steps. Thus, Metnase plays a role
in the integration of foreign DNA into host human cell
genomes, and it may therefore be a valuable target for
therapeutic suppression of HIV infection. HIV preferen-
tially targets certain regions of the human genome and
Metnase does not inﬂuence this preference. It is not yet
known whether Metnase promotes random integration of
plasmid DNA and it is possible that Metnase preferentially
integrates DNA into the *7,000 Mariner remnants in the
human genome. Non-targeted DNA integration is a major
obstacle to efﬁcient, homologous recombination-directed
gene targeting in human cells. Knocking down Metnase or
chemically inhibiting its integration activity holds promise
for enhancing gene targeting that may direct the develop-
ment of safer and more effective gene therapy strategies.
Metnase in DNA repair
We hypothesized that Metnase, given its histone modifying
activity, and its DNA binding and cleavage activity, could
play a role in DNA repair. We focused on DSBs since they
are required for chromosomal translocations, and since
DSBs enhance exogenous DNA integration, a function to
which Metnase contributes (Lee et al. 2005). DSBs are
repaired by two major pathways: homologous recombina-
tion (HR) and non-homologous end joining (NHEJ).
Metnase over-expression had no impact on DSB repair by
HR, but it signiﬁcantly enhanced NHEJ (Lee et al. 2005).
Metnase knockdown by siRNA reduced imprecise NHEJ
by 12-fold and precise NHEJ by 20-fold. Mutations in
essential residues within the SET or the transposase
domains abrogated the NHEJ enhancing activity of Metn-
ase. Interestingly, a single substitution (D490S) in the
transposase domain had a dominant negative effect,
repressing NHEJ below levels seen with endogenous
Metnase (Fig. 3). Metnase overexpression also enhances
cell survival after exposure to ionizing radiation, which
generates DSBs (Lee et al. 2005). We therefore addressed
whether Metnase interacts with known components of the
NHEJ pathway. We found that Metnase co-immunopre-
cipitates with the essential NHEJ component DNA Ligase
IV (Hromas et al. 2008), which mediates the ﬁnal re-liga-
tion step in NHEJ repair. As mentioned above, Metnase
interacts with Pso4 (Beck et al. 2008). Pso4 is a multi-
functional protein implicated in RNA splicing and DNA
repair (Mahajan and Mitchell 2003) among other pro-
cesses. Pso4 binds double-stranded DNA and forms a sta-
ble complex with Metnase on both TIR and non-TIR DNA,
and this interaction is required for the activity of Metnase
activity in NHEJ repair. Both proteins co-localize with
Nbs1 foci at DSB regions, and knocking down Pso4 with
siRNA ablated Metnase localization at DSB foci (Beck
Fig. 3 Role of Metnase in NHEJ. Metnase binds DNA DSBs in the
presence of Pso4, and then interacts with DNA Ligase IV, which
catalyzes the ﬁnal ligation step. This ﬁgure does not include the
potential ways by which Metnase could enhance NHEJ repair by
modifying chromatin structure through its H3K36 histone methylase
activity. As noted in the text, SET domain mutations interfere with the
ability of Metnase to enhance NHEJ, implying that histone methyl-
ation is indeed important for its activity in NHEJ repair. The crystal
structure of Metnase has been deposited in the structure database
(3B05, 3F2k) although not published, and it appears that Metnase
exists as a dimer
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types of DNA lesions, such as inter-strand cross-links
(Zhang et al. 2005). Pso4 is also present in a complex with
the XAB2 protein which is important in transcription-
coupled repair of DNA (Kuraoka et al. 2008). This last
interaction, in addition to Pso4 role in RNA splicing, and
the role of Metnase in H3k36 methylation (which corre-
lates with transcription elongation), suggests potential
functions for Metnase and Pso4 in transcription-coupled
nucleotide excision repair.
Metnase may have roles in other DNA repair processes.
Endonucleases in general contribute to NHEJ repair by
processing the free DNA ends, and to nucleotide excision
repair by excising single-strand DNA ﬂanking bulky DNA
lesions. Pso4 has been implicated in repair of DNA cross-
links, and Metnase nicking activity could contribute to
processing of these types of lesions. During NHEJ, Metn-
ase over-expression decreases the length of the deletions
seen at the repair site (Hromas et al. 2008), perhaps
reﬂecting reduced end-processing due to accelerated repair.
It is unclear whether Metnase enhancement of DNA repair
is mediated primarily through its histone methylation or
DNA endonuclease activities, but as mentioned above
mutations in either of these two domains decrease NHEJ
repair. Of note, histone methylation in other settings has
been shown to create docking sites for DNA repair pro-
teins, such as H4K20 methylation that attracts 53BP1
(Botuyan et al. 2006). We have unpublished evidence that
Metnase increases the presence of H3K36Me2 at the DSB
using chromatin immunoprecipitation, and that this meth-
ylation of H3K36 assists in recruiting NHEJ components,
such as the MRN complex and DNA Ligase IV, to the
DSB. This may be ultimately the major role of Metnase in
NHEJ repair.
Metnase in decatenation and chemotherapy resistance
Given its endonucleolytic activity on supercoiled DNA, we
postulated a role for Metnase in chromosomal decatena-
tion. DNA replication results in intertwined sister chro-
matids that must be untangled, or decatenated, to ensure
proper chromatid segregation in mitosis, and to prevent
catastrophic chromatid breaks during anaphase (Ashworth
2005). TopoIIa is the principal decatenating enzyme. It
functions by creating transient DSBs through which it
passes double-stranded DNA (Roca 2009). We demon-
strated that Metnase interacts with TopoIIa by co-immu-
noprecipitation, that these proteins colocalize on condensed
chromosomes, and that Metnase enhances TopoIIa decat-
enation activity (Williamson et al. 2008b). Nuclear extracts
containing Metnase decatenated highly interlocked (kine-
toplast) DNA to relaxed circular forms more rapidly than
those lacking Metnase, and neutralizing anti-sera against
Metnase reversed that effect. Overexpression of Metnase
was found to promote progression through the metaphase
decatenation checkpoint induced by TopoIIa inhibitors
(Williamson et al. 2008b; Wray et al. 2009a, b). We have
preliminary data indicating that Metnase promotes survival
after treatment with agents that cause DNA replication
stress by enhancing restart of stalled and/or collapsed
replication forks. These roles in the replication stress
response may also depend on its interaction with TopoIIa,
which may be important for relaxing positive supercoils in
frontofprogressingreplicationforks(McClendonetal.2005).
We recently demonstrated that Metnase is expressed at
high levels in several acute myeloid leukemia (AML) and
breast cancer cell lines (Wray et al. 2009a, b). In the AML
cells, Metnase was expressed at much higher levels than in
CD34? hematopoietic progenitors, the normal cell coun-
terpart to AML cells (Wray et al. 2009a). In both the breast
cancer and AML cells, we showed that Metnase interacts
with TopoIIa. Also, we found that knocking down Metnase
signiﬁcantly increased metaphase decatenation checkpoint
arrest induced by the TopoIIa inhibitor ICRF-193 in both
the breast cancer and AML cells (Wray et al. 2009a, b).
Importantly, knocking down Metnase markedly sensitized
breast cancer cells to the TopoIIa inhibitor adriamycin,
which is widely used in the treatment of breast cancer. In
like manner, knocking down Metnase markedly sensitized
AML cells tothe widely used leukemiadrug etoposide. Also,
adding Metnase to TopoIIa blocked the inhibitory effects of
both adriamycin and etoposide on TopoIIa-dependent decat-
enation in vitro (Wray et al. 2009a, b). These results suggest
Metnase as a critical target for small molecule inhibition to
enhance the effects of cancer chemotherapy, at least those
involving with TopoIIa inhibitors.
Metnase in replication fork restart
Using BRDU incorporation and ﬂow cytometry, we found
that Metnase promotes cell proliferation, but it does not
alter cell cycle phase distributions, or the speed of repli-
cation fork progression. However, Metnase knock-down
greatly sensitized cells to replication stress induced by
hydroxyurea, UV light, and the topoisomerase I inhibitor
camptothecin. Such knock-downs conferred a marked
defect in restart of stalled replication forks. Metnase also
promotes resolution of phosphorylated H2Ax foci, a mar-
ker of DNA double-strand breaks at collapsed forks.
Metnase was also found to co-immunoprecipitates with
PCNA, and RAD9, a member of the PCNA-like RAD9-
RAD1-HUS1 (9-1-1) complex that has key roles in the
intra-S checkpoint, and the restart of stalled forks. Using
DNA ﬁber analysis, we found that altering Metnase levels
564 Genetica (2010) 138:559–566
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correlate with the rate at which forks could restart after
stalling in the presence of hydroxyurea. Reducing Metnase
levels decreased signiﬁcantly the ability of stalled repli-
cation forks to restart, as determined with DNA ﬁber
analysis (DeHaro et al. 2010). Metnase also promotes
TopoIIa-mediated relaxation of positively supercoiled
DNA, which would decrease torsional stress in front of rep-
lication forks. Together these results establish Metnase as a
key factor that promotes restart of both stalled and collapsed
replication forks. This could be due to enhanced TopoIIa
activity in front of the stalled fork, promoting PCNA stabil-
ization of the replisome at the stalled fork, and/or promoting
9-1-1 complex activity at the stalled fork. Interestingly, in
unpublished experiments, we have recently found that
Metnase is phosphorylated at S495 by Chk1 after ionizing
radiationorhydroxyurea,consistentwithitsroleinreplication
fork restart. Of course, the ability of Metnase to promote
restartofstalledreplicationsforkscouldbeduetoitsintrinsic
histone methylase or endonuclease activities as well.
Conclusion
Metnase is a unique and intriguing transposase-related
protein for many reasons: (1) it is present only in primates,
(2) it fuses histone methylase activity with DNA structure-
speciﬁc endonuclease activity, (3) it enhances DNA repair
by NHEJ, (4) it promotes foreign DNA integration, (5) it
enhances TopoIIa function, and (6) it promotes replication
fork restart after stalling. It is important to develop small
molecule inhibitors of Metnase because it promotes resis-
tance to common cancer chemotherapeutics and promotes
HIV integration. It represents a domesticated transposase:
transposase biochemical activities that cause genome
rearrangements and might predispose to malignancy have
been subverted by primates to enhance DNA repair and
genome stability. It is ironic that Metnase, instead of
mobilizing DNA segments and moving them to alternative
locations, promotes repair of free DNA ends. There are
certainly unrecognized activities of Metnase, especially in
its interactions with heterochromatin, where it might reg-
ulate unknown replication, transcriptional, or DNA repair
processes. Given the wide activities of Metnase, one of the
major goals of future investigation is to deﬁne whether
there is a common mechanism for these activities, or
whether they are based on distinct interacting partners.
One of the most intriguing features of Metnase is its
presence solely in primates. Genome stability is certainly
important for all organisms throughout evolution, and
Metnase may have arisen late in response to increasing
threats posed by invading transposons. There are certainly
other possible explanations for its late arrival. For example,
there is a mental retardation syndrome with a deletion at
3p26 near Metnase, and it is intriguing to speculate that
Metnase may play a role in neuronal stability (Higgins
et al. 2004). Other interesting questions are how can a
protein that arose so recently interact with proteins
involved in critical aspects of DNA dynamics and regulate
so many important cellular functions? One answer derives
from the fact that the SET and transposase domains of
Metnase were each present long before they fused in pri-
mates. Thus, the separate domains probably evolved
interaction partners independently, long before the gene
fusion event. In this view, the fusion brought together
distinct biochemical activities and interaction partners,
yielding novel beneﬁcial biochemical properties. Primate
cells may have become addicted to Metnase function,
selecting for its presence in those mammals. However,
some thought must also be given to what was lost by this
fusion. Since the SET domain of Metnase was present long
before its fusion with the transposase, it is possible that
losing this distinct SET activity might beneﬁcially alter
transcriptional regulation of gene expression during pri-
mate evolution. In like manner, the development of
Metnase clearly altered the classic biochemical function of
its transposase domain, which may have altered genomic
stability in primates. Thus, the loss of speciﬁc activities by
this fusion may have also played an important yet undis-
covered role in primate development. In summary, Metn-
ase is a unique transpose-derived protein that regulates
several key cellular functions, and will therefore likely to
continue to be a fertile area of study.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and source are credited.
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